Press Releases

Date	Title	Company
11-Dec-2023	ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma	Businesswire
11-Dec-2023	MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study	MorphoSys AG
10-Dec-2023	Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B	Businesswire
10-Dec-2023	Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting	Businesswire
10-Dec-2023	GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia	Businesswire
10-Dec-2023	Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023	Businesswire
10-Dec-2023	Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting	Businesswire
10-Dec-2023	Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023	Businesswire
09-Dec-2023	New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)	Businesswire
09-Dec-2023	Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting	Businesswire
09-Dec-2023	New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A	Businesswire
09-Dec-2023	BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s Warrants	AccessWire
09-Dec-2023	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Businesswire
08-Dec-2023	MEDFINITI Introduces HemWell MD: Along with its Breakthrough in Hemorrhoid Technology "HemWell"	AccessWire
08-Dec-2023	Ribometrix Demonstrates Rapid Progress for eIF4E Program at San Antonio Breast Cancer Symposium	Businesswire
08-Dec-2023	Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease	Businesswire
08-Dec-2023	Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	Businesswire
08-Dec-2023	Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment	Businesswire
08-Dec-2023	Biosurgery Market Analysis: Innovations, Trends, and Growth Trajectories \| CAGR 9.1%	The Wire Times
08-Dec-2023	Cell Analysis Market: Unraveling Innovations and Growth Trajectories \| CAGR 9.5%	The Wire Times